Document is current
Any future updates will be listed below
-
Authors
Flouri, Irini https://orcid.org/0000-0002-6966-1304
Goutakoli, Panagiota https://orcid.org/0009-0008-1436-7803
Repa, Argyro https://orcid.org/0000-0002-1044-2449
Bertsias, Antonios https://orcid.org/0000-0003-3515-2488
Avgoustidis, Nestor https://orcid.org/0000-0003-3436-4016
Eskitzis, Anastasios https://orcid.org/0009-0008-5667-6348
Pitsigavdaki, Sofia https://orcid.org/0000-0001-9422-3931
Kalogiannaki, Eleni https://orcid.org/0009-0004-7930-3545
Terizaki, Maria https://orcid.org/0009-0004-5901-6047
Bertsias, George https://orcid.org/0000-0001-5299-1406
Sidiropoulos, Prodromos https://orcid.org/0000-0001-9607-0326
-
Funding
Funding for this research was provided by:
Pfizer Pharmaceuticals (55999165)
University of Crete
- License Information
-
More Information
Article History
Received: 27 June 2023
Accepted: 1 September 2023
First Online: 10 October 2023
Declarations
:
: AR: Honoraria for lectures/presentations from MSD&Lilly and support for attending meetings from Abbvie; NA: Honoraria for lectures/presentations from Abbvie, Pfizer&Lilly and support for attending meetings from Abbvie, MSD&Pfizer; GB: Consulting fees from AstraZeneca&GS, and honoraria for lectures/presentations from Pfizer, Novartis, UCB, Aenorasis&GSK; PS: Research grants from Pfizer, MSD, Abbvie, Lilly, Novartis, Amgen, consulting fees from Abbvie, Pfizer, Lilly; IF, AB, AE, SP, EK, MT: No conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Institutional Review-Board of the University Hospital of Heraklion, Crete (decision-number:1476/20-03-2012).
: Written informed consent was obtained from all participants included in the study regarding their participation and publishing of anonymized data.
